Divalproex Sodium
Product Images NDC 43353-547

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 43353-547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 500mg (43353 547)

This is a medication called Divalproex NA ER which comes in a bottle of 60 tablets, each containing 500mg of the active ingredient. The NDC number for this medication is 43353-0547-53. The medication is manufactured by Mylan Pharmaceuticals Inc. The package was repackaged by Aphena Pharma BI85. The medication is used for treating seizures, bipolar disorder, and preventing migraines.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Divalproex Structural Formula (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 01)

FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 02)

The text describes a chart or graph showing the percentage reduction in CPS rate of patients taking Divalproex Sodium Delayed-Release compared to placebo. It indicates that 50% of patients experienced improvement while the rest experienced either no change or worsening.*

FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 03)

This appears to be a chart showing the reduction in CPS rate for patients taking either high or low dose delayed-release divalproex sodium or divalproex sodium. The chart also shows the percentage of patients who experienced improvement, no change, or worsening.*

FDA Label Image

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 04)

FDA Label Image

Mylan Logo (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.